2014 HIV R4P Satellite: Help End AIDS Together: Towards Vaccine and Cure For HIV/AIDS
27 October 2014 | Cape Town, South Africa

The most recent breakthroughs highlighted how approaches to prevent infection and to control viral replication and transmission are closely associated. New insights into the induction and role of bnAbs, T-cell repsonses and immune-based therapies are proving crucial in both vaccine and cure research.

To this end, the International AIDS Society (IAS) Towards an HIV Cure initiative and the International AIDS Vaccine Initiative (IAVI) hosted a joint satellite session during the HIV R4P Conference in Cape Town, South Africa on Monday 27 October 2014.

The satellite session enhanced the understanding and collaboration between vaccine and cure researchers, improved understanding of synergies, potential and perspectives, and increased dialogue with advocates, communities, policy makers, public health experts and funders, with an aim to:

  • Accelerate research for both vaccines and immune-based interventions to control viral replication;
  • Strengthen the case for sustained political and financial commitment to innovation and research of new approaches;
  • Advance the thinking and dialogue on future directions and priorities in research, as well as frameworks and mechanisms for facilitating and supporting more collaborative research;
  • Bring the science closer to the affected communities and ensure that future innovation is accessible to and acceptable for those who need it most.

Agenda

Introduction and Welcome
Linda-Gail Bekker, Desmond Tutu HIV Centre and Margaret McGlynn, IAVI

Benefits of enhanced collaboration between cure and vaccine research
Carl Dieffenbach, DAIDS, NIAID-NIH

Vaccine research today and tomorrow
Wayne Koff, IAVI

Broadly neutralizing antibodies in vaccine and cure research
John Mascola, VRC, NIAID-NIH

T-cell and vector approaches in vaccine and cure research
Louis Picker, Oregon Health and Science University

Q&A with panel and audience
Linda-Gail Bekker, Desmond Tutu HIV Centre and Margaret McGlynn, IAVI